Monica Gonzalez
Primary Care · Lindsay, CANPI 1972971422
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 219 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 219 payments — averaging $17.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$883
- Novo Nordisk$797
- Lilly USA, LLC$732
- Sunovion Pharmaceuticals Inc.$306
- AbbVie$275
- Sumitomo Pharma America, Inc.$233
- plus $498 from 12 others
What the payments were for
- Food & beverage$3,717100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 34 | $883 |
| Novo Nordisk | 52 | $797 |
| Lilly USA, LLC | 35 | $732 |
| Sunovion Pharmaceuticals Inc. | 34 | $306 |
| AbbVie | 15 | $275 |
| Sumitomo Pharma America, Inc. | 25 | $233 |
| Boehringer Ingelheim | 8 | $204 |
| Amgen | 5 | $84 |
| Amarin Pharma, Inc. | 2 | $34 |
| Abbott | 1 | $32 |
| Exact Sciences | 1 | $22 |
| Novartis | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $17 |
| Merck | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Organon | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,723 in reported general payments places this provider in the 90th percentile of 706 primary care providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 72 | $109,557 |
| Xigduo XrDapaglifloz Propaned/Metformin | 90 | $80,012 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 58 | $63,565 |
| OzempicSemaglutide | 68 | $63,343 |
| FarxigaDapagliflozin Propanediol | 53 | $63,032 |
| JardianceEmpagliflozin | 55 | $58,542 |
| SynjardyEmpagliflozin/Metformin Hcl | 54 | $44,575 |
| MounjaroTirzepatide | 29 | $28,483 |
| EntrestoSacubitril/Valsartan | 20 | $25,621 |
| GemtesaVibegron | 19 | $22,913 |
| Dapagliflozin-Metformin ErDapaglifloz Propaned/Metformin | 32 | $20,915 |
| Tresiba Flextouch U-100Insulin Degludec | 43 | $14,950 |
| TradjentaLinagliptin | 18 | $14,438 |
| LinzessLinaclotide | 16 | $12,944 |
| EliquisApixaban | 11 | $12,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimSynjardy Xr, Jardiance, Synjardy, Tradjenta | $204 | $181,120185 claims |
| Novo NordiskRybelsus, Ozempic | $797 | $172,901140 claims |
| AstraZenecaFarxiga | $883 | $63,03253 claims |
| Lilly USA, LLCMounjaro, Humulin 70-30 | $732 | $29,98641 claims |
| NovartisEntresto | $21 | $25,62120 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $233 | $22,91319 claims |
| AbbVieLinzess | $275 | $12,94416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 706 primary care providers in California.
Other primary care in Lindsay
- Leslie FletcherTorrance$1.8M
- Hamideh PourzandLos Angeles$103K
- Veronica RamirezSacramento$83K
- Tyson FieldstedBakersfield$65K
- Kathryn CooperSan Diego$31K
- Shalaine Corbillala Mesa$22K
- Paula StoddardHanford$22K
- Ashley LoweSan Diego$19K
- Vanessa LeeLong Beach$16K
- Lynda TranHuntington Beach$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.